Clinical Trials Logo

Bronchiectasis clinical trials

View clinical trials related to Bronchiectasis.

Filter by:

NCT ID: NCT01677403 Recruiting - Bronchiectasis Clinical Trials

A Study to Access Safety and Efficacy of Nebulized Tobramycin in Patients With Bronchiectasis

Start date: August 2012
Phase: Phase 4
Study type: Interventional

This is a study to evaluate the efficacy,indications,adverse reactions and resistance of combined administration of nebulized tobramycin compared with systemic administration alone in patients with Bronchiectasis in acute exacerbation of Bronchiectasis.

NCT ID: NCT01615484 Completed - Cystic Fibrosis Clinical Trials

Ex-vivo Perfusion and Ventilation of Lungs Recovered From Non-Heart-Beating Donors to Assess Transplant Suitability

Start date: September 2013
Phase: N/A
Study type: Interventional

The purpose of this research study is to learn about the safety of transplanting lungs obtained from non-heart-beating donors (NHBDs) that have been ventilated (attached to a breathing machine or ventilator to deliver oxygen) and perfused with a lung perfusion solution (Steen solution™, made by Vitrolife). This ventilation and perfusion will be done outside the body (ex-vivo) in a modified cardiopulmonary bypass circuit (the kind of device used routinely during most heart surgeries). The purpose of performing ex-vivo perfusion and ventilation is to learn how well the lungs work, and whether they are likely safe to transplant.

NCT ID: NCT01580748 Not yet recruiting - Clinical trials for Symptomatic Bronchiectasis

Phase2, Single Group, Open Clinical Trial to Evaluate the Efficacy and Safety of Roflumilast in Symptomatic Bronchiectasis Patients

Start date: May 2012
Phase: Phase 2
Study type: Interventional

There is currently no effective treatment of bronchiectasis other than treating its complications such as infection, bleeding, etc. Roflumilast is a newly developed anti-inflammatory drug that has proven to be effective in stable COPD. We hypothesized that Roflumilast might be effective in symptomatic bronchiectasis patients

NCT ID: NCT01578681 Completed - Bronchiectasis Clinical Trials

ELTGOL and Bronchiectasis. Respiratory Therapy

ELTGOLBQ
Start date: September 2011
Phase: N/A
Study type: Interventional

The ELTGOL technique improves mucociliary clearance in adult patients with bronchiectasis. Primary objective: -To evaluate the efficacy of ELTGOL in stable state patients with bronchiectasis compared to placebo. Secondary objectives: - To evaluate the level of knowledge of airway clearance techniques and adherence to them in patients with bronchiectasis. - To assess the side effects during the procedure: oxygen desaturation, increased dyspnea and hemoptysis.

NCT ID: NCT01569009 Completed - Bronchiectasis Clinical Trials

Physical Activity in Bronchiectasis

PhAB
Start date: June 2012
Phase: N/A
Study type: Observational

The primary aim of this study is to examine the physical activity levels of patients with bronchiectasis. Subsidiary aims are: 1. To examine whether there is a relationship between the physical activity levels of patients with bronchiectasis and clinical phenotype (disease severity, exercise capacity, quality of life or other symptoms of their disease). The investigators also want to explore the relationship between physical activity levels and readiness to change physical activity behaviour (stages of change, self-efficacy, decisional balance and processes of change). 2. To assess the feasibility and acceptability of the physical activity assessment tools: ActiGraph, ActivPAL, pedometer and the International Physical Activity Questionnaire. Hypothesis: Patients with bronchiectasis will have low levels of physical activity, and this is related to their clinical phenotype (disease severity, exercise capacity, quality of life and other symptoms of their disease) and also their readiness to change physical activity behaviour (stages of change, self-efficacy, processes of change and decisional balance).

NCT ID: NCT01515007 Completed - Clinical trials for Non Cystic Fibrosis Bronchiectasis

Phase 3 Study With Ciprofloxacin Dispersion for Inhalation in Non-CF Bronchiectasis (ORBIT-3)

Start date: March 31, 2014
Phase: Phase 3
Study type: Interventional

This study (ARD-3150-1201, ORBIT-3) will evaluate the safety and efficacy of inhaled Pulmaquin (ciprofloxacin dispersion for inhalation) compared to inhaled placebo in subjects who have a confirmed diagnosis of non-cystic fibrosis (non-CF) bronchiectasis with a history of pulmonary exacerbations and chronic P. aeruginosa infections.

NCT ID: NCT01480882 Completed - Clinical trials for Chronic Obstructive Pulmonary Disease (COPD)

Efficacy and Safety Study of a Percussion Device to Mobilise Sputum From Respiratory Passage

LEGA
Start date: December 2011
Phase: Phase 2/Phase 3
Study type: Interventional

A Malaysian company by name Formedic Technologies SDN BHD has devised a hand held machine which is supposed to mimic the chest percussion performed by professional physiotherapist to mobilize sputum through the respiratory passage. The aim of this study is to compare the effectiveness and safety of this mechanical percussion device in the treatment of airway clearance with conventional chest physiotherapy carried out by qualified physiotherapists in patients suffering from bronchiectasis or Chronic obstructive Pulmonary disease (COPD).

NCT ID: NCT01463371 Completed - Bronchiectasis Clinical Trials

Effects of Azithromycin on Airway Oxidative Stress Markers in Patients With Bronchiectasis

Start date: October 2006
Phase: N/A
Study type: Interventional

The mechanism by which macrolide antibiotics have immune modifying effects independent from its antibacterial activity has not been well established. In the present work, the investigators will analyze the effect of long-term treatment with azithromycin (250 mg three times per week during three months) on airway oxidative stress markers in exhaled breath condensate of adult patients with stable non-CF bronchiectasis.

NCT ID: NCT01410422 Recruiting - COPD Clinical Trials

Metabolomic Analysis of Exhaled Breath Condensates in Patients With COPD and Bronchiectasis

Start date: May 2011
Phase: N/A
Study type: Observational

Metabolomics is a large-scale approach to monitoring the compounds involved in cellular processes. It may reflect changes in biological function. Collection of exhaled breath is a newly developed, noninvasive method that may allow clinicians and researchers to assess biochemical profiles in the airway. This study is conducted for the metabolomic analysis of the exhaled gas in patients with Chronic Obstructive Pulmonary Disease (COPD) and bronchiectasis.

NCT ID: NCT01354912 Recruiting - Bronchiectasis Clinical Trials

The Incidence of Nontuberculous Mycobacterial Pulmonary Infection in Bilateral Bronchiectasis and Bronchiolitis

Start date: May 2011
Phase: N/A
Study type: Observational

Nontuberculous mycobacteria (NTM) are ubiquitous organisms in the environment and are now increasingly being recognized as significant causes of chronic pulmonary infection in immunocompetent individuals (1). The most frequently encountered NTM lung disease worldwide is caused by Mycobacterium avium-intracellular complex (MAC) (2-4). In several studies with chest computed tomography (CT), researchers have demonstrated that the presence of bilateral multifocal bronchiolitis (well-defined small nodules and branching centrilobular nodules, or tree-in-bud pattern) and bronchiectasis distributed mainly in the right middle lobe and lingular segment are indicative of NTM pulmonary infection (7-11). Accordingly, it is believed that radiologic findings of bilateral bronchiolitis and bronchiectasis on chest CT scans specifically suggest NTM pulmonary infection (1). These CT findings, however, may not be specific for NTM pulmonary infection. CT patterns of bronchiectasis and bronchiolitis in the pulmonary infections caused by various NTM organisms have been reported, and these organisms include Mycobacterium kansasii, Mycobacterium xenopi, and rapidly growing mycobacteria such as Mycobacterium abscessus, Mycobacterium fortuitum, and Mycobacterium chelonae (12-14). In addition, not all patients with bronchiectasis and bronchiolitis have NTM pulmonary infection. Two recent studies showed that only about 50% of patients with such CT features have MAC pulmonary infection (9,15). To the best of our knowledge, however, there is no report about the incidence of NTM in patients with bronchiectasis or bronchiolitis in countries with low incidence of TB. Thus, the purpose of our study was to determine the frequency of NTM pulmonary infection in patients with bilateral bronchiectasis and bronchiolitis at chest CT and to investigate whether these CT findings are specifically indicative of MAC infection or other specific pathogen.